FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

NeoMedical Screw System for Late-stage Tumors

FDA clears a Neo Medical 510(k) for the use of its Pedicle Screw System in late stage tumor indications in combination with Osartis BonOs Inject cemen...

Human Drugs

Tyvaso DPI Pulmonary Hypertension NDA Accepted

FDA accepts for priority review a United Therapeutics NDA for Tyvaso DPI (inhaled treprostinil) for treating pulmonary arterial hypertension.

Human Drugs

FDA Real-World Evidence in Cancer Treatment Study

FDA opens a five-year collaboration with ConcertAI to evaluate real-world outcomes and safety in cancer treatments.

Medical Devices

Attorney Sees Positive Step in Pauls VITAL Act

Attorney Jeffrey Shapiro says legislation sponsored by Sen. Rand Paul to have CMS take the lead in the regulation of laboratory-developed tests could ...

Federal Register

Comments Sought on Study Data Exchange Standards

Federal Register notice: FDA seeks comments on the use of study data exchange standards from stakeholders involved in study conduct, data collection, ...

Federal Register

510(k) Exemption Petition: Powered Patient Transport

Federal Register notice: FDA announces that it received a petition requesting exemption from the premarket notification requirements for the generic d...

Human Drugs

FDA Claims Transparency, Value for Complex Generic Drugs

OGD Office of Research and Standards director Robert Lionberger describes steps FDA has taken to foster the development of complex generic drugs.

Human Drugs

Sanofi Aubagio Data Not Sufficient for New Indication: FDA

FDA says Sanofi did not submit sufficient data to justify approving an Aubagio sNDA for an indication for pediatric patients with relapsing forms of m...

Biologics

StrataGraft Approved for Thermal Burns

FDA approves Stratatechs StrataGraft, a cellularized scaffold for treating adult patients with certain thermal burns.

Federal Register

Notice Correction on ANDA Approval Withdrawal

Federal Register notice: FDA corrects a 5/12 notice about the withdrawal of approval of 12 ANDAs from multiple applicants.